Latest news with #LexeoTherapeutics
Business Insider
2 days ago
- Business
- Business Insider
Lexeo Therapeutics price target lowered to $15 from $20 at Chardan
Chardan lowered the firm's price target on Lexeo Therapeutics (LXEO) to $15 from $20 and keeps a Buy rating on the shares after the company reported Q2 results and affirmed upcoming catalysts for its LX2006 and LX2020 programs. The firm said it awaits further visibility on focus and strategy, but thinks a non-viral approach could be 'quite interesting.' Chardan added that it updated its Lexeo model for Q2 financials, including dilution from the May offering. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
29-07-2025
- Business
- Yahoo
Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 7, Stifel reiterated its 'Buy' rating for Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a price target of $21. This decision came after the company announced that the FDA gave Breakthrough Therapy Designation to its treatment called LX2006. A scientist in a laboratory examining a test tube filled with a medication used to treat hypertension and cardiovascular diseases. The FDA granted Breakthrough Therapy Designation for LX2006 in both cardiac and neurologic measures of Friedreich ataxia (FA). Lexeo Therapeutics, Inc. (NASDAQ:LXEO) also shared that LX2006 has been selected to participate in the FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program, which is designed to expedite clinical development timelines. Stifel sees the Breakthrough Therapy Designation as a good sign for Lexeo Therapeutics, Inc.'s (NASDAQ:LXEO) regulatory prospects. The firm noted that this designation suggests that the FDA may be more flexible for rare disease gene therapies. Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company focused on developing therapies for cardiovascular diseases. While we acknowledge the potential of LXEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Business Insider
14-06-2025
- Business
- Business Insider
Lexeo Therapeutics files to sell 41.63M shares of common stock for holders
16:10 EDT Lexeo Therapeutics (LXEO) files to sell 41.63M shares of common stock for holders Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
13-05-2025
- Business
- Business Insider
Lexeo Therapeutics price target lowered to $20 from $22 at Chardan
Chardan analyst Geulah Livshits lowered the firm's price target on Lexeo Therapeutics (LXEO) to $20 from $22 and keeps a Buy rating on the shares. The firm is updating its model following the company's Q1 results, reiterated guidance on its LX2006 and LX2020 programs, as well as its update on its cash position, the analyst tells investors in a research note. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
